We compared in-hospital and one-year clinical outcomes in patients undergoing debulking followed by stent implantation versus stenting alone for saphenous vein graft (SVG) aortoostial lesions.
Treatment of saphenous vein graft (SVG) aortoostial lesions by conventional balloon angioplasty or new devices (laser or atherectomy) has been associated with suboptimal results, frequent periprocedural complications and higher rates of restenosis (1) (2) (3) . These disappointing results can be attributed, in part, to the excessive residual stenosis and unyielding plaque. Stents have been found to improve short-and long-term outcomes compared with percutaneous transluminal coronary angioplasty (PTCA) or atherectomy when used for aortoostial lesions (4 -6) . However, even with stents the risk of restenosis remains high. It has been suggested that debulking the atherosclerotic plaque or altering the lesion compliance with atheroablative devices before stent implantation may improve procedural and late clinical outcomes in this complex lesion subset.
Thus, to determine the acute and late clinical outcomes associated with stent implantation with or without prior debulking for SVG aortoostial lesions, we evaluated procedural success, major in-hospital complications and one-year clinical outcomes in a large consecutive series of patients.
Database treated with Palmaz-Schatz stent implantation between September 1995 and March 1997. All patients gave written informed consent approved by the Institutional Review Board of the Washington Hospital Center before the procedure. These patients represent the majority (Ͼ95%) of patients with SVG aortoostial lesions treated during the study period, as the strategy was to implant stents in all SVG aortoostial lesions, and only patients with distal embolization and reduced flow did not receive stents. Patients were divided into two groups according to the type of intervention used. All indications for stent use (planned elective use to improve acute procedural safety and reduce late clinical events, provisional use to treat suboptimal primary device results or urgent use to treat abrupt or threatened closure) are included in this study. Debulking with excimer laser (n ϭ 90), directional atherectomy (n ϭ 39) and transluminal extraction atherectomy (n ϭ 10) was performed in 139 lesions before stenting (group I), and 201 lesions were treated with stents alone (group II).
Baseline demographic characteristics and in-hospital events were recorded by independent hospital chart review. Clinical follow-up data were obtained by office visits or serial telephone interviews by research nurses. All records relevant to late clinical events (death, Q wave myocardial infarction [MI] and any revascularization) and target lesion revascularization were obtained and evaluated by an independent adjudication committee. In addition to target lesion revascularization, repeat revascularization is also reported per patient (as any repeat revascularization) and includes all target lesion and target vessel revascularizations.
Definitions. Procedural success was defined as a final diameter stenosis Ͻ50% in the absence of major inhospital complications (death, Q wave MI and coronary artery bypass surgery [CABG] ). A diagnosis of Q wave MI was made when there was documentation of pathological Q waves (Ͼ0.04 s) on an electrocardiogram (ECG) in conjunction with elevation of creatinine phosphokinase greater than twice the upper limit of normal. Non-Q wave MI was defined as creatinine kinase-MB (CK-MB) enzyme elevation Ն5 times the upper limit of normal in the absence of new pathological Q waves. Degenerated SVG were those with ectasia or lumen irregularity comprising Ն50% of the SVG shaft length. Ectasia was a lumen Ͼ20% larger than the user-defined reference segment. For the purpose of this study, ostial lesions were defined as within 3 mm of the proximal anastomosis.
Stent types and deployment technique.
The types of stents used were either coronary (n ϭ 114, 28.7%) or "biliary" Palmaz-Schatz (n ϭ 282, 71.3%) (Johnson and Johnson Interventional Systems, Warren, New Jersey). Stent implantation procedures were performed using techniques described previously (7, 8) . Coronary stents were used for vessels Յ4 mm and a larger biliary version was selected for vessels Ͼ4 mm in diameter. The lesion was crossed with a 0.014 in floppy or extrasupport guide wire, and either prior balloon angioplasty or atheroablation was performed before stent implantation. Adjunct high-pressure PTCA was performed after initial stent deployment (14 to 16 atms) in all cases. Intravascular ultrasound (IVUS) imaging was performed in 270 (79.4%) lesions pretreatment, poststent implantation and postadjunct PTCA. Optimal stent implantation was carefully monitored using an interactive technique with prespecified IVUS end points and additional high-pressure inflations if needed. The IVUS was used to optimize stent apposition, expansion (minimal stent area Ն80% of the distal reference lumen area) and lesion coverage. In addition, IVUS enabled the detection of outflow obstruction and residual dissection at stent margins.
All patients were pretreated with aspirin and continued their standard antianginal therapy. A bolus of 10,000 U of intravenous heparin was given after insertion of femoral arterial sheath. After the initial administration, a repeat bolus of 5,000 U was given to maintain the activated clotting time (ACT) Ͼ300 s, if necessary. Heparin was stopped immediately after the procedure, and the sheath was removed when the ACT was Ͻ150 s. All patients received ticlopidine at a dose of 250 mg twice daily for four weeks. Abciximab (Centocor, Malvern, Pennsylvania) was used in Ͻ5% of patients. Emboli containment devices were not used in any patients.
Atheroablation. Device selection was based on vessel size, preprocedural lesion morphology (lesion eccentricity, ulceration, degeneration, irregularity, calcification and thrombus) and the absence of clinical contraindications at the discretion of the operator. Directional atherectomy (Devices for Vascular Intervention, Redwood City, California) was chosen for eccentric lesions located in the nondegenerated SVG Ն3 mm in diameter (n ϭ 39, 28%). The procedure was performed according to the previously described technique (9) . Most commonly a 7F atherectomy device was used. In
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The excimer laser angioplasty (Spectranetics/Advanced Interventional System, Colorado Springs, Colorado) was selected for smaller or degenerated SVG (n ϭ 90, 64.7%). The ELCA procedure was performed as described elsewhere (11) . In brief, the range of the laser fiber catheter used was 1.7 mm to 2.0 mm. Energy densities ranged from 25 to 65 mJ/mm 2 (mean 57.9 Ϯ 5.4 mJ/mm 2 ), and the number of pulses ranged from 30 to 1,880 (mean, 339 Ϯ 352). A single laser pass technique was used in most of the cases.
Adjunct balloon angioplasty was performed in all atheroablation cases before stent implantation to ensure adequate stent expansion.
Angiographic analysis. All cineangiograms were analyzed with the use of a computer-assisted, automated edge-detection algorithm (ARTREK, Quantitative Cardiac System, Ann Arbor, Michigan) by a core angiographic laboratory that was blinded to the clinical outcome. With the outer diameter of the contrast filled catheter as the calibration standard, reference and minimal lumen diameters (MLDs) were determined before and after stent implantation, and post final PTCA from multiple projections and the results from the "worst" view were recorded. Based upon these measurements, percent diameter stenoses were determined. Standard morphologic criteria were used for the identification of lesion length ("shoulder-to-shoulder"), eccentricity, irregularity, fluoroscopic calcification and ulceration.
IVUS imaging protocol. Intravascular ultrasound studies were performed with the Boston Scientific Corporation/ Cardiovascular Imaging System. This system incorporated a single-element 30-MHz transducer and an angled mirror mounted on the tip of a flexible shaft that was rotated at 1,800 rpm within a 3.2F short monorail polyethylene imaging sheath to form planar cross-sectional images in real time. All IVUS studies were performed after administration of 0.2 mg of intragraft nitroglycerin. The ultrasound catheter was advanced Ϸ10 mm beyond the target lesion, and a slow imaging run (using automated transducer pullback at 0.5 mm/s) was performed from beyond the target lesion to the aortoostial junction. A number of cross-sectional measurements were made, and validation of these measurements by IVUS has been reported previously (12, 13) . By using computerized planimetry (TapeMeasure, Indec Systems, Mountain View, California), lesion site and reference segment external elastic membrane (EEM) cross-sectional area (CSA) and lumen CSA were measured. Because media thickness cannot be measured accurately, plaque plus media (P ϩ M) CSA (EEM CSA minus lumen CSA) was used as a measure of atherosclerotic plaque. Plaque burden (crosssectional narrowing) was calculated as the P ϩ M CSA divided by the EEM CSA. When the atherosclerotic plaque encompassed the catheter, the lumen was assumed to be the size of the imaging catheter. The reference segment selected was the most visually normal cross section within 10 mm distal to the lesion.
Statistical analysis. Statistical analysis was performed using StatView 4.5 or SAS (14) (both SAS Institute Inc, Cary, North Carolina). Categorical data are presented as percent frequency and compared between groups by chi square statistics. Continuous variables are presented as mean Ϯ one standard deviation, and comparison between the groups was performed using unpaired t test. Cox (15) proportional hazard regression analysis was used to determine independent correlates of target lesion revascularization (TLR) and late cardiac events. Survival curves were constructed by Kaplan Meier method and displayed using the SAS LIFETEST procedure. The Wilcoxon log rank test was used for survival comparison between groups. A p value Յ0.05 was considered statistically significant.
RESULTS
Baseline demographics. The baseline characteristics of all treated patients are listed in Table 1 . The groups were well matched except for a higher incidence of previous MI in the stent alone group and a trend for more diabetic patients in the debulking and stent group. The treated grafts were relatively old with an average graft age of 96.3 Ϯ 58.6 months.
Angiographic analysis and procedural characteristics.
Lesion characteristics and quantitative angiographic measurements are presented in Tables 2 and 3 . Eccentric lesions were more frequent in group I as compared with group II (63.6% vs. 46.8%, p ϭ 0.02). The prevalence of degenerated SVG, ulceration, thrombus containing and restenotic lesions was similar for the two groups, most likely related to the small sample size. Likewise, there was no difference in the average pretreatment and posttreatment angiographic reference diameter. Interestingly, despite a smaller MLD and greater baseline diameter stenosis in group I, the final MLD was greater and diameter stenosis was lower.
A total of 396 stents were deployed in 320 patients with 340 lesions. The mean number of stents per lesion was 1.17 Ϯ 0.45. In 289 (85.0%) lesions, a single stent was used, and 51 (15.0%) lesions were treated with two stents. Average balloon size was 4.36 Ϯ 0.79, and mean final inflation pressure was 15.1 Ϯ 4.2. The average balloon-toartery ratio used for final stent expansion was 1.30 Ϯ 0.25.
IVUS analysis.
Quantitative IVUS findings are presented in Table 4 . Preintervention, lesions treated with plaque debulking and stenting had smaller MLD and lumen CSA. Conversely, these lesions had larger P ϩ M CSA and greater plaque burden (Table 4) . Postintervention, these lesions had lesser plaque burden as compared with lesions treated with stents alone.
Procedural results. Overall procedural success was high and similar for the two groups (Table 5) . Similarly combined major in-hospital complications (death, Q wave MI and emergent CABG) did not differ significantly between the groups (2.2% vs. 2.6%, p ϭ 0.24). Likewise, the CSA ϭ cross-sectional area; EEM ϭ external elastic membrane; IVUS ϭ intravascular ultrasound; MLD ϭ minimal lumen diameter; P ϩ M ϭ plaque ϩ media.
plasty or CABG) and for TLR at one-year follow-up are shown in Figure 2 . Event-free survival was similar in both groups for both end points (p ϭ 0.48 for any event and p ϭ 0.12 for TLR). Cox regression analysis was performed to determine the independent correlates of any adverse cardiac events and TLR at one-year follow-up. The following variables were entered into the multivariable model: age, gender, graft age, diabetes, hypertension, previous history of MI, types of stents, prestent atheroablation, MLD before and after intervention, preintervention and final reference lumen diameter, plaque burden and final lumen CSA by IVUS. 
DISCUSSION
This study shows that patients with SVG aortoostial lesions treated with stent implantation with or without prior atheroablation have: 1) similar in-hospital procedural results and major complications, and 2) similar one-year cardiac events, including TLR and any repeat revascularization. In this large patient cohort, we also identified independent predictors of TLR and late cardiac events. Lumen CSA by IVUS and restenotic lesions were found to predict both TLR and adverse cardiac events at one year. Interestingly, in none of these analyses did prestent atheroablation predict TLR or adverse cardiac end points.
Treatment of SVG aortoostial lesions.
Overall procedural success rate of balloon angioplasty in SVG varies between 84% and 92% (1,2). Procedural success is lower in aortoostial location compared with nonostial locations (1,2). Conventional balloon angioplasty is frequently unsuccessful in this location due to greater elastic recoil. Several investigators have demonstrated that stent use in SVG aortoostial lesions is associated with high procedural success and low complication rates (16 -18) . Furthermore, in a retrospective comparison of stenting and balloon angioplasty for SVG aortoostial lesions, Brener et al. (4) have shown that patients in the stent group had a lower incidence of composite end points of death, MI and repeat revascularization (23% vs. 45%, p Ͻ 0.001) at one-year follow-up (12) . Likewise, Rocha-Singh et al. (6) reported a 93% procedural success rate and 27% restenosis rate with Palmaz-Schatz stent implantation in ostial SVG lesions. In another study involving stent implantation in SVG aortoostial in patients with unstable angina, Rechavia et al. (5) have shown high immediate success and low 30-day and long-term event rates.
However, no study has addressed the issue of whether atheroablation before stenting in this lesion subset could improve the immediate and late clinical outcomes compared with stenting alone. In this study comparing two strategies for the treatment of SVG aortoostial lesions, we found no difference in the immediate and late outcomes after stenting with or without prestent athero- ablation. Device selection was based on vessel size, anatomy, preprocedural lesion morphology (lesion eccentricity, ulceration, irregularity, calcification and thrombus) and degeneration of the graft. De novo lesions involving the ostium of the larger (Ͼ3 mm) nondegenerated graft were treated with directional atherectomy followed by stent implantation or balloon angioplasty followed by stent insertion. Lesions located in the ostium of the smaller vein grafts were treated with excimer laser angioplasty and stents or stents alone. Due to the relatively small sample size in each group, there was no statistical difference in the baseline lesion characteristic.
Overall major in-hospital complications (death, Q wave MI and CABG) were infrequent in both treatment groups despite lesion complexity. However, there was a relatively high frequency of periprocedural non-Q wave MI after both types of treatment (18.2% in group I and 18.5% in group II, p ϭ 0.60). This high prevalence of non-Q wave MI perhaps represents a very complex subset of lesions in diffusely diseased SVG grafts. Several reports have indicated an association between periprocedural CK-MB elevations and late adverse cardiac events (19, 20) , and this could also account for high late mortality in our study. Only a minority (Ͻ5%) of patients was treated with glycoprotein IIb/IIIa inhibitor, and distal protection devices were not used in this study.
Stent synergy (prestent atheroablation) approach. The rationale of this strategy was to test the hypothesis of whether atheroablation before stenting could facilitate subsequent optimal stent expansion and whether this optimal stent expansion translates into improved long-term outcome. Although with this approach we were able to achieve a larger final MLD (3.43 Ϯ 0.76 mm vs. 3.21 Ϯ 0.70 mm; p ϭ 0.05) and less residual plaque burden (57.6 Ϯ 10.69% vs. 64.9 Ϯ 11.05%; p ϭ 0.01), no impact on the procedural and late clinical outcome was demonstrated. The most likely explanation may be that the atheroablation is not sufficient to have a long-term impact. Compared with the reference diameter of 3.5 mm, the atheroablative devices create relatively small lumen (1.7 mm to Ͻ3 mm). This is illustrated by the relatively large residual plaque burden (approximately 60%). 
